Emerging Threat Report: Fourth Quarter (2016)
The DEA's Special Testing and Research Laboratory’s Emerging Trends Program compiled the data for this report to monitor new psychoactive substance (NPS) trends in the United States through queries of archived seizure and analysis information from drug evidence analyzed by the DEA laboratory system. This Fourth Quarter 2016 Report includes NPS seized and identified in the fourth quarter of CY2016. For opioids and analgesics, this report indicates that "Acryl fentanyl and P-Fluorobutyrylfentanyl were reported for the first time in the fourth quarter of 2016. The relative percentage of fentanyl identifications decreased from between 65 and 70% in previous quarters to 50% due to the significant increase (300%) in furanyl fentanyl identifications during the fourth quarter."
From the report document: "This is not a comprehensive list of all new psychoactive substances and is not representative of all evidence analyzed by DEA. This data is a quarterly snapshot of the new psychoactive substance market in the United States. The term new psychoactive substance (NPS) describes a recently emerged drug that may pose a public health threat. This includes synthetic cannabinoids, substituted cathinones, phenethylamines, opioids, tryptamines, benzodiazepines, and a variety of other chemical classes. Due to the recent increase in seizures, fentanyl is also included in this report. An identification is made when authenticated reference material is available for comparison. When reference material is not available, the drug evidence is identified as 'substance unconfirmed.'”
"A single unit of drug evidence may have multiple sub-units. For the purposes of this document, each unit of drug evidence counts as one identification regardless of the number of sub-units. Some seized drug evidence contains more than one active ingredient; therefore, more than one identification can be made for a single unit."